You are here
The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.
CMEC Meeting 38, 29 November 2002
Complementary Medicines Evaluation Committee
Extracted ratified minutes
Public recommendation summary
This summary has been posted immediately after the CMEC meeting to give quick advice of the recommendations made by CMEC to the TGA. This summary does not represent the decisions of TGA. Reasons underlying these recommendations will be available after Members ratify the Minutes at the next CMEC meeting.
CMEC confirms that the draft Minutes of its previous meeting (CMEC 37, 29 - 30 August 2002), as amended, are a true and accurate record of that previous meeting.
Item 7.1 Aristolochia spp. and aristolochic acids for therapeutic use
CMEC notes the safety review conducted by the TGA and endorses the current regulatory status prohibiting the use of medicines containing Aristolochia spp. and aristolochic acids.
CMEC notes the safety review conducted by the TGA and recommends that it maintain Larrea tridentata as a listable substance, but with a revised warning statement for oral products.
|CMEC 38 Extracted ratified minutes (pdf)||102KB|